Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC
Recruiting · NCT04324151 · Observational (researchers observe without assigning treatment) · Lead sponsor: Hunan Province Tumor Hospital
View the official record on ClinicalTrials.gov →What this trial is about
This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
- Potentially Resectable NSCLC
- Treatment Plan is Crizotinb or Standard Chemotherapy
Exclusion criteria
- Patients with contraindication of chemotherapy
- Pregnant or breast feeding women
Where it is running
1 location listed.
- Yongchang Zhang - Changsha, Hunan, China